Company / Return on Equity (ROE)
Jazz Pharmaceuticals Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-8.3%
FY2025
5-year range
-8.3% / 16.8%
FY2021-FY2025
Trend
-160.3%
vs FY2024
Sector context
#58 of 190
Health Care
What the data says
Jazz Pharmaceuticals reports negative total equity of -8.3% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-8.3% in FY2025 with a 5-year CAGR of -24.5%.
Declined from 11.1% to -8.3% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -14.8pp
- 5-Year Change
- -24.5pp
- 10-Year Change
- -
Sector benchmark
#58 of 190 in Health CareTop 31% of 190This company -8.3% Sector average -50.4%
▼
+83.6% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 160.3% year-over-year.
- Currently 42.2pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -8.3% | -160.3% |
| FY2024 | 13.7% | +23.2% |
| FY2023 | 11.1% | +70.2% |
| FY2022 | 6.5% | -61.2% |
| FY2021 | 16.8% | +3.8% |
| FY2020 | 16.2% | -9.8% |
| FY2019 | 18.0% | +22.9% |
| FY2018 | 14.6% | -18.6% |
| FY2017 | 18.0% | +322.1% |
| FY2016 | 4.3% | -79.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026